BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17804674)

  • 1. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass.
    Diekmann F; Rovira J; Carreras J; Arellano EM; Bañón-Maneus E; Ramírez-Bajo MJ; Gutiérrez-Dalmau A; Brunet M; Campistol JM
    J Am Soc Nephrol; 2007 Oct; 18(10):2653-60. PubMed ID: 17804674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
    Bonegio RG; Fuhro R; Wang Z; Valeri CR; Andry C; Salant DJ; Lieberthal W
    J Am Soc Nephrol; 2005 Jul; 16(7):2063-72. PubMed ID: 15917339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
    Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
    Ko HT; Yin JL; Wyburn K; Wu H; Eris JM; Hambly BD; Chadban SJ
    Nephrol Dial Transplant; 2013 Feb; 28(2):327-36. PubMed ID: 23229928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
    Krämer S; Wang-Rosenke Y; Scholl V; Binder E; Loof T; Khadzhynov D; Kawachi H; Shimizu F; Diekmann F; Budde K; Neumayer HH; Peters H
    Am J Physiol Renal Physiol; 2008 Feb; 294(2):F440-9. PubMed ID: 18094032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
    Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction.
    Rovira J; Arellano EM; Carreras J; Campos B; Vodenik B; Bañón-Maneus E; Ramírez-Bajo MJ; Moya-Rull D; Solé-González A; Hernández A; Revuelta I; Quintana LF; Howat WJ; Campistol JM; Diekmann F
    Transplantation; 2009 Sep; 88(5):646-52. PubMed ID: 19741461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
    Keller K; Daniel C; Schöcklmann H; Endlich KH; Kerjaschki D; Johnson RJ; Hugo C
    Nephrol Dial Transplant; 2006 Oct; 21(10):2724-35. PubMed ID: 16861242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor in chronic rat allograft nephropathy.
    Malmström NK; Kallio EA; Rintala JM; Nykänen AI; Räisänen-Sokolowski AK; Paavonen T; Lemström KB; Koskinen PK
    Transpl Immunol; 2008 May; 19(2):136-44. PubMed ID: 18503889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
    Torras J; Herrero-Fresneda I; Gulias O; Flaquer M; Vidal A; Cruzado JM; Lloberas N; Franquesa Ml; Grinyó JM
    Nephrol Dial Transplant; 2009 Dec; 24(12):3632-40. PubMed ID: 19671594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
    Letavernier E; Legendre C
    Transplant Rev (Orlando); 2008 Apr; 22(2):125-30. PubMed ID: 18631865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, improved renal microvascular insufficiency in 5/6 nephrectomized rats.
    Song J; Meng L; Li S; Qu L; Li X
    Vascul Pharmacol; 2009; 50(5-6):185-93. PubMed ID: 19563735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration.
    Saurina A; Campistol JM; Lario S; Oppenheimer F; Diekmann F
    Transplant Proc; 2007 Sep; 39(7):2138-41. PubMed ID: 17889117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis.
    Rangan GK; Coombes JD
    Nephrol Dial Transplant; 2007 Aug; 22(8):2175-82. PubMed ID: 17550925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and mechanism of mammalian target of rapamycin in age-related renal cell senescence and organ aging.
    Zhuo L; Cai G; Liu F; Fu B; Liu W; Hong Q; Ma Q; Peng Y; Wang J; Chen X
    Mech Ageing Dev; 2009 Oct; 130(10):700-8. PubMed ID: 19698731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.